Supernus Pharmaceuticals (NASDAQ:SUPN) Lowered to Buy Rating by StockNews.com

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by stock analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday.

Separately, Cantor Fitzgerald reissued a “neutral” rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $31.70 on Thursday. The firm has a market cap of $1.77 billion, a PE ratio of 29.63 and a beta of 0.74. Supernus Pharmaceuticals has a one year low of $25.53 and a one year high of $40.28. The firm’s fifty day moving average is $31.86 and its two-hundred day moving average is $34.89.

Insider Buying and Selling

In related news, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. The trade was a 10.56 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 9.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. PNC Financial Services Group Inc. lifted its stake in shares of Supernus Pharmaceuticals by 4.7% during the first quarter. PNC Financial Services Group Inc. now owns 16,097 shares of the specialty pharmaceutical company’s stock valued at $527,000 after buying an additional 726 shares during the period. Commerce Bank lifted its holdings in shares of Supernus Pharmaceuticals by 12.9% during the 1st quarter. Commerce Bank now owns 15,025 shares of the specialty pharmaceutical company’s stock valued at $492,000 after acquiring an additional 1,720 shares in the last quarter. Jefferies Financial Group Inc. boosted its position in shares of Supernus Pharmaceuticals by 230.5% in the first quarter. Jefferies Financial Group Inc. now owns 81,313 shares of the specialty pharmaceutical company’s stock worth $2,663,000 after buying an additional 56,713 shares during the period. Natixis Advisors LLC boosted its holdings in Supernus Pharmaceuticals by 3.4% in the 1st quarter. Natixis Advisors LLC now owns 40,391 shares of the specialty pharmaceutical company’s stock worth $1,323,000 after acquiring an additional 1,324 shares during the period. Finally, Arkadios Wealth Advisors purchased a new position in shares of Supernus Pharmaceuticals in the first quarter valued at $550,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.